Keri Eisenberg joined Alliance for Cancer Gene Therapy (ACGT) at the beginning of 2023 as the chief philanthropy officer. Her near-20 years of fundraising and stewardship experience includes: a nonprofit organization for people with Parkinson’s disease; and one of the top university-affiliated medical institutions in the world.

As ACGT’s  chief philanthropy officer, Ms. Eisenberg is responsible for strategically developing ACGT’s fundraising initiatives and fostering philanthropic alliances with individual donors, corporations, medical institutions, nonprofit partner organizations and other stakeholders committed to advancing cell and gene therapy for cancer.

“My role is to serve as a bridge between passionate donors whose dream is to have a lasting impact and the scientists and researchers who are making transformative discoveries in the new frontier of cancer treatment,” says Ms. Eisenberg, who has a personal reason to help drive the progress of new cancer therapies.

When a loved one was diagnosed with stage 4 melanoma, Ms. Eisenberg put faith in the physicians and researchers at the comprehensive cancer center where her loved one received treatment, including immunotherapy. Despite the discouraging prognosis, her trust was rewarded – and this experience inspires her to give hope to others experiencing the same fight with cancer.

“He has now been in remission for a year and untethered by his diagnosis while he enjoys life with his wife and children. His story is one of hope and optimism, but like many, I have been devastated by the loss of loved ones and friends to cancer,” says Ms. Eisenberg, who combined her passion for fundraising with the medical field in 2013 when she became the Senior Director of Development for UCLA Health Sciences. “I am honored to join ACGT where our acute focus is on realizing a cancer-free future following promising ideas from bench to bedside. I cannot think of greater reward than helping people fulfill their dreams, foster hope and deliver new therapeutics to patients faster.”